JoinMedical Chroniclefor a free, CPD-accredited one-hour webinar on the topic: Beyond UVA-UVB protection; High Energy Visible Blue Light, the new frontier. The is webinar is sponsored by Pierre Fabre. 

This webinar will be presented by Dermatologist Dr Johann de Wet

It will be presented by Dermatologist Dr Johann de Wet. 

Date: 24 January 2022  

Time: 19h00  

Topic: Beyond UVA-UVB protection; High Energy Visible Blue Light, the new frontier  

Presenter: Dr Johann de Wet 

Register here

 

Bio 

Dr Johann de Wetis a dermatologist and Mohs Micrographic Surgeon in private practice in Stellenbosch. Dr de Wet was awarded his Fellowship from the College of Dermatologists with distinction and obtained his MMed degree in Dermatology from the University of Stellenbosch Cum Laude. He is also a graduate of the University of Cardiff in Wales and of the University of Queensland, Australia, where he obtained a Diploma in Dermatology and an MMed in Skin Cancer. Dr De Wet is also a fellowship-trained Mohs Micrographic Surgeon through the American Society of Dermatological Surgery. He also holds an academic appointment as an Honorary lecturer at the Division of Dermatology at Stellenbosch University. A keen clinician, academic and researcher, Dr De Wet has published various articles in peer-reviewed journals. He regularly appears as an invited speaker at both local and international conferences.  

His interests include medical dermatology, dermatological surgery and skin cancer. Dr De Wet is the recipient of accolades such as the Jansen Research Foundation medal and the Peter Gordon-Smith medal for excellent achievement in the Fellowship examinations of the College of Dermatologists of South Africa. He was also awarded the Discovery Foundation Academic Research Fellowship Award for his work on melanoma skin cancer and Mohs Micrographic Surgery. Most recently he was awarded the Stellenbosch University Rector’s medical for excellent academic achievement. He is currently pursuing a Master’s degree in Pathology at the University of Stellenbosch focussing on the treatment of Lentigo Maligna.